BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The approach of Maher et al (2009) further demonstrated the use of deep-transcriptome sequencing (in this case, a combination of 454 Life Sciences long reads and Illumina GA short reads were used) to identify potential fusions, with initial proof of principle being to rediscover the BCR–ABL fusion in CML and the recurrent TMPRSS2-ERG gene fusion in prostate cancer.